From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial – a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants?
Muhammad Qaseem, Mian Sajjad Ali, Shehbaz Ali, Abdul Haseeb Hasan · 2026
Read From pancreatic ductal adenocarcinoma to non-small cell lung cancer: daraxonrasib in the RASolute 302 trial – a pan-RAS(ON) breakthrough or the next evolution in targeting diverse oncogenic RAS variants? by Muhammad Qaseem, Mian Sajjad Ali, Shehbaz Ali, Abdul Haseeb Hasan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13354368.txt.
Description
Muhammad Qaseem and co-authors write to the editor in 2026 about a new drug for cancers driven by a stuck growth switch. Such tumors, led by pancreatic and lung cancers, grow fast and resist most care.
The letter hails fresh trial results for the drug, which grabs the switch in its on state across its main forms. It locks the switch by first binding a helper protein, forming a pair that jams the switch's partners. Lab tests show deep growth blocks at low doses. The authors ask whether the drug marks a true pan switch breakthrough or a next step in a longer chase.
Catalog record
| CREATOR | Muhammad Qaseem, Mian Sajjad Ali, Shehbaz Ali, Abdul Haseeb Hasan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |